

FILED

MAY 07 2018

Judge James F. Hyland

IN RE: REGLAN LITIGATION

SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: MIDDLESEX COUNTY

CASE NO.: 289
Civil Action

MASTER DOCKET: MID-L-10165-14

CASE MANAGEMENT ORDER NO. 31

THIS MATTER having been brought before the Court at a case management conference on April 4, 2018, and counsel for plaintiffs and counsel for defendants having been present, and for good cause shown,

IT IS on this 7 day of May, 2018,

ORDERED THAT plaintiff Dalivian Dorsey (L-10135-14), or her appointed guardian or other representative, and her counsel shall appear in person or by video for a *Friendly* hearing to approve settlement immediately following the next case management conference scheduled for May 24, 2018.


IT IS ALSO ORDERED THAT counsel for plaintiff Dalivian Dorsey, Napoli Shkolnik, PLLC, shall notify plaintiff, or her appointed guardian or other representative, in writing, of this Order and the scheduled *Friendly* hearing. In advance of the scheduled *Friendly* hearing, counsel for plaintiff shall also submit a proposed order and certification of services within ten (10) days from the date of this Order. If the plaintiff, or her appointed guardian or other representative, and her counsel fail to appear for the *Friendly* hearing, then counsel for Alaven, Schwarz, and Wyeth are permitted to file a proposed order converting the basis for dismissal with prejudice of claims asserted against them.

IT IS FURTHER ORDERED THAT the “opt-out” Plaintiffs represented by Ralph Pittle, Esq. and Michael Levin, Esq. (Donald R. Benton (L-10173-14), Gloria Eidson (L-10248-14), Marie Goodson (L-010337-14), Cecil Holbrook (L-10272-14), Lazaro Martinez (L-10482-14), and Judy McIntosh (L-10172-14)) shall have until May 14, 2018 to serve any additional evidence of product identification and to file motions, if any, to vacate prior dismissals of PLIVA, Inc. (“PLIVA”), Watson Laboratories, Inc. (“Watson”) and Teva Pharmaceuticals USA, Inc. (“Teva”), as the case may be. If no such motions are filed by such date, PLIVA, Watson and Teva may move to convert any prior without prejudice dismissals in these cases to with prejudice dismissals.

IT IS FURTHER ORDERED THAT the counsel for the “opt-out” Plaintiffs Basil Downer (L-10379-14), Ruth Jennings (L-10041-14), Jay Price (L-10052-14), Michelle Schwartz (L-10457-14), Melanie Villa (L-10053-14), Gail Young (L-10421-14) shall reserve all medical, pharmacy, and employment records to counsel for the remaining Generic Defendants on or before April 24, 2018.

IT IS FURTHER ORDERED THAT the remaining Generic Defendants and the “opt-out” Plaintiffs represented by Theodore Oshman, Esq. (Basil Downer (L-10379-14), Ruth Jennings (L-10041-14), Jay Price (L-10052-14), Michelle Schwartz (L-10457-14), Melanie Villa (L-10053-14), Gail Young (L-10421-14)) will use their best efforts to complete the depositions of these “opt-out” plaintiffs by June 30, 2018, and to complete the depositions of their prescribing physicians by August 30, 2018.

SO ORDERED:



HONORABLE James F. Hyland, J.S.C.